Madrigal Pharmaceuticals
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 276
- Market Cap
- $5.5B
- Introduction
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03038022
- Locations
- ๐ฉ๐ฐ
Madrigal Research Site, Viborg, Denmark
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT02912260
- Locations
- ๐บ๐ธ
Madrigal Research Site, Seattle, Washington, United States
Drug Interaction Study of MGL-3196 With Atorvastatin
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02749578
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02542969
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01519531
- Locations
- ๐บ๐ธ
PRACS Institute (formerly Cetero Research), Fargo, North Dakota, United States
Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01367873
- Locations
- ๐บ๐ธ
Cetero Research, Fargo, North Dakota, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath